My interview with CCMB director, clarifies a big doubt we& #39;ve had:
"Nothing Very Unusual About SARS-CoV-2 In India That Makes It More Or Less Virulent" https://www.indiaspend.com/nothing-very-unusual-about-sars-cov-2-in-india-that-makes-it-more-or-less-virulent/">https://www.indiaspend.com/nothing-v...
"Nothing Very Unusual About SARS-CoV-2 In India That Makes It More Or Less Virulent" https://www.indiaspend.com/nothing-very-unusual-about-sars-cov-2-in-india-that-makes-it-more-or-less-virulent/">https://www.indiaspend.com/nothing-v...
This responds to what gov scientists in Gujarat claimed, that there are diff strains and that high COVID19 mortality rates in Gujarat may be due to "more virulent strain" https://economictimes.indiatimes.com/news/politics-and-nation/wuhans-l-strain-may-be-behind-gujarats-high-death-rate-experts/articleshow/75390437.cms">https://economictimes.indiatimes.com/news/poli...
3. CCMB is keen for private companies to come forward, take their research &run with it: "Companies can come forward ... We can license it at really negligible fees. As a government lab, we are not supposed to make money out of this but whatever technologies can go to public..."
4. Rakesh Mishra says CCMB is working w/ @Bioconlimited and @SyngeneIntl on.... "something really dramatic called ‘Next Generation Sequencing’. With this project, we will be able to test 10,000 or 20,000 samples in one go."
Idea came from @broadinstitute. https://www.indiaspend.com/nothing-very-unusual-about-sars-cov-2-in-india-that-makes-it-more-or-less-virulent/">https://www.indiaspend.com/nothing-v...
Idea came from @broadinstitute. https://www.indiaspend.com/nothing-very-unusual-about-sars-cov-2-in-india-that-makes-it-more-or-less-virulent/">https://www.indiaspend.com/nothing-v...